Post-earnings recap
Reported
Wed, Jul 28, 2021
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Soleno Therapeutics reported a loss per share that was worse than expected, but the stock still rose by 2.79%. This increase may reflect investor optimism about the company's future clinical developments despite the lack of revenue guidance. The market seems to be looking past the EPS miss, focusing instead on long-term potential.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.14 | N/A | -75.00% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach due to the current market conditions. They emphasized their commitment to ongoing clinical development.
Management did not provide specific revenue guidance for the upcoming quarters.
The company remains focused on advancing its clinical programs.